We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluation of ITX 5061, a Scavenger Receptor B1 Antagonist: Resistance Selection and Activity in Combination With Other Hepatitis C Virus Antivirals.
- Authors
Haihong Zhu; Wong-Staal, Flossie; Haekyung Lee; Syder, Andrew; McKelvy, Jeffrey; Schooley, Robert T.; Wyles, David L.
- Abstract
ITX 5061 is a scavenger receptor B1 antagonist that has entered phase 1 clinical trials in hepatitis C virus (HCV)-infected humans. We evaluated ITX 5061 in combination with interferon-&alpa;, ribavirin, and HCV protease and polymerase inhibitors in a genotype 2a infectious virus system. ITX 5061 is a potent inhibitor of HCV replication and is additive to synergistic with interferon-α, ribavirin, BILN2061, VX950, VX1, and 2'-C-methyladenosine. Resistance selection experiments were performed using a Jc1-FEO virus co-culture system and intermittent ITX 5061 exposure under neomycin selection. We identified a mutant virus with a substitution of aspartic acid for asparagine at the highly conserved position 415 in E2 (N415D). Introduction of this mutation into wild-type virus conferred high-level resistance to ITX 5061. There was no cross-resistance between ITX 5061 and HCV protease inhibitors or interferon-α. These results suggest that ITX 5061 is a promising compound for study in combination with other HCV inhibitors.
- Publication
Journal of Infectious Diseases, 2012, Vol 205, Issue 4, p656
- ISSN
0022-1899
- Publication type
Academic Journal
- DOI
10.1093/infdis/jir802